Close Menu

kidney injury

The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

The company reported $38.4 million in total revenues for the quarter and said testing services revenues rose 46 percent year over year.

The firm believes the multi-part stratification project will help further commercialization of its KidneyIntelX blood-based assay for acute and chronic kidney disease. 

CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.

The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.

AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.

The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.

The Medicare contractor has proposed to cover the non-invasive test for certain kidney and heart transplant patients.

The UCSF spinout aims to develop noninvasive tests to detect kidney injury for the transplantation field and to diagnose and monitor chronic disease.

The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.